A graduate of Stanford University and Yale University, Fuad El-Hibri has professional experience in a number of industries, including the biopharmaceutical sphere. At present, Fuad El-Hibri serves as executive chairman of the board at Emergent BioSolutions, a global biopharmaceutical company he founded in 1998.
In July 2017, Emergent BioSolutions announced that the Medical CBRN Defense Consortium (MCDC), an initiative of the Department of Defense’s Joint Project Manager for Medical Countermeasure Systems, has awarded the company a five-year, $23 million contract to create a new multidrug auto-injector. Envisioned for both military and civilian use, the intramuscular device would be used to deliver nerve agent antidotes in case of accidental or intentional exposure.
